Palermo Marina S, Exeni Ramón A, Fernández Gabriela C
Lab Inmunologia, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina P. de Melo 3081 (C1425AUM), Ciudad de Buenos Aires, Argentina.
Expert Rev Anti Infect Ther. 2009 Aug;7(6):697-707. doi: 10.1586/eri.09.49.
The typical form of hemolytic uremic syndrome (HUS) is the major complication of Shiga toxin-producing Escherichia coli infections. HUS is a critical health problem in Argentina since it is the main cause of acute renal failure in children and the second cause of chronic renal failure, accounting for 20% of renal transplants in children and adolescents in Argentina. Despite extensive research in the field, the mainstay of treatment for patients with HUS is supportive therapy, and there are no specific therapies preventing or ameliorating the disease course. In this review, we present the current knowledge about pathogenic mechanisms and discuss traditional and innovative therapeutic approaches, with special focus in Argentinean contribution. The hope that a better understanding of transmission dynamics and pathogenesis of this disease will produce better therapies to prevent the acute mortality and the long-term morbidity of HUS is the driving force for intensified research.
溶血性尿毒症综合征（HUS）的典型形式是产志贺毒素大肠杆菌感染的主要并发症。HUS在阿根廷是一个严重的健康问题，因为它是儿童急性肾衰竭的主要原因，也是慢性肾衰竭的第二大原因，占阿根廷儿童和青少年肾移植的20%。尽管该领域进行了广泛研究，但HUS患者的主要治疗方法仍是支持性治疗，尚无预防或改善病程的特异性疗法。在本综述中，我们介绍了关于致病机制的当前知识，并讨论传统和创新治疗方法，特别关注阿根廷的贡献。希望对该疾病传播动力学和发病机制的更好理解能产生更好的疗法，以预防HUS的急性死亡率和长期发病率，这是加强研究的驱动力。
